Literature DB >> 25662840

KCNN Genes that Encode Small-Conductance Ca2+-Activated K+ Channels Influence Alcohol and Drug Addiction.

Audrey E Padula1, William C Griffin1, Marcelo F Lopez1, Sudarat Nimitvilai1, Reginald Cannady1, Natalie S McGuier1, Elissa J Chesler2, Michael F Miles3, Robert W Williams4, Patrick K Randall1, John J Woodward1, Howard C Becker1, Patrick J Mulholland1.   

Abstract

Small-conductance Ca(2+)-activated K(+) (KCa2) channels control neuronal excitability and synaptic plasticity, and have been implicated in substance abuse. However, it is unknown if genes that encode KCa2 channels (KCNN1-3) influence alcohol and drug addiction. In the present study, an integrative functional genomics approach shows that genetic datasets for alcohol, nicotine, and illicit drugs contain the family of KCNN genes. Alcohol preference and dependence QTLs contain KCNN2 and KCNN3, and Kcnn3 transcript levels in the nucleus accumbens (NAc) of genetically diverse BXD strains of mice predicted voluntary alcohol consumption. Transcript levels of Kcnn3 in the NAc negatively correlated with alcohol intake levels in BXD strains, and alcohol dependence enhanced the strength of this association. Microinjections of the KCa2 channel inhibitor apamin into the NAc increased alcohol intake in control C57BL/6J mice, while spontaneous seizures developed in alcohol-dependent mice following apamin injection. Consistent with this finding, alcohol dependence enhanced the intrinsic excitability of medium spiny neurons in the NAc core and reduced the function and protein expression of KCa2 channels in the NAc. Altogether, these data implicate the family of KCNN genes in alcohol, nicotine, and drug addiction, and identify KCNN3 as a mediator of voluntary and excessive alcohol consumption. KCa2.3 channels represent a promising novel target in the pharmacogenetic treatment of alcohol and drug addiction.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25662840      PMCID: PMC4839516          DOI: 10.1038/npp.2015.42

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  64 in total

1.  Gene coexpression networks in human brain identify epigenetic modifications in alcohol dependence.

Authors:  Igor Ponomarev; Shi Wang; Lingling Zhang; R Adron Harris; R Dayne Mayfield
Journal:  J Neurosci       Date:  2012-02-01       Impact factor: 6.167

2.  Withdrawal from intermittent ethanol exposure increases probability of burst firing in VTA neurons in vitro.

Authors:  F Woodward Hopf; Miquel Martin; Billy T Chen; M Scott Bowers; Maysha M Mohamedi; Antonello Bonci
Journal:  J Neurophysiol       Date:  2007-08-15       Impact factor: 2.714

3.  Naltrexone modification of drinking effects in a subacute treatment and bar-lab paradigm: influence of OPRM1 and dopamine transporter (SLC6A3) genes.

Authors:  Raymond F Anton; Konstantin K Voronin; Patrick K Randall; Hugh Myrick; Abraham Tiffany
Journal:  Alcohol Clin Exp Res       Date:  2012-05-02       Impact factor: 3.455

4.  Reduced nucleus accumbens SK channel activity enhances alcohol seeking during abstinence.

Authors:  F Woodward Hopf; M Scott Bowers; Shao-Ju Chang; Billy T Chen; Miguel Martin; Taban Seif; Saemi L Cho; Kay Tye; Antonello Bonci
Journal:  Neuron       Date:  2010-03-11       Impact factor: 17.173

Review 5.  K(Ca)2 channels: novel therapeutic targets for treating alcohol withdrawal and escalation of alcohol consumption.

Authors:  Patrick J Mulholland
Journal:  Alcohol       Date:  2012-03-30       Impact factor: 2.405

6.  Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR.

Authors:  G E Swan; A M Valdes; H Z Ring; T V Khroyan; L M Jack; C C Ton; S J Curry; T McAfee
Journal:  Pharmacogenomics J       Date:  2005       Impact factor: 3.550

7.  Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study.

Authors:  Lara A Ray; Kent E Hutchison
Journal:  Arch Gen Psychiatry       Date:  2007-09

8.  Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch.

Authors:  Elaine C Johnstone; Patricia L Yudkin; Kate Hey; Sarah J Roberts; Sarah J Welch; Michael F Murphy; Siân E Griffiths; Robert T Walton
Journal:  Pharmacogenetics       Date:  2004-02

9.  An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study.

Authors:  Raymond F Anton; Gabor Oroszi; Stephanie O'Malley; David Couper; Robert Swift; Helen Pettinati; David Goldman
Journal:  Arch Gen Psychiatry       Date:  2008-02

10.  Transcriptional profiling of C57 and DBA strains of mice in the absence and presence of morphine.

Authors:  Dorothy E Grice; Ilkka Reenilä; Pekka T Männistö; Andrew I Brooks; George G Smith; Greg T Golden; Joseph D Buxbaum; Wade H Berrettini
Journal:  BMC Genomics       Date:  2007-03-16       Impact factor: 3.969

View more
  28 in total

Review 1.  Pharmacological gating modulation of small- and intermediate-conductance Ca(2+)-activated K(+) channels (KCa2.x and KCa3.1).

Authors:  Palle Christophersen; Heike Wulff
Journal:  Channels (Austin)       Date:  2015-07-28       Impact factor: 2.581

2.  Differential potassium channel gene regulation in BXD mice reveals novel targets for pharmacogenetic therapies to reduce heavy alcohol drinking.

Authors:  Jennifer A Rinker; Diana B Fulmer; Heather Trantham-Davidson; Maren L Smith; Robert W Williams; Marcelo F Lopez; Patrick K Randall; L Judson Chandler; Michael F Miles; Howard C Becker; Patrick J Mulholland
Journal:  Alcohol       Date:  2016-06-27       Impact factor: 2.405

Review 3.  Promising pharmacogenetic targets for treating alcohol use disorder: evidence from preclinical models.

Authors:  Jennifer A Rinker; Patrick J Mulholland
Journal:  Pharmacogenomics       Date:  2017-03-27       Impact factor: 2.533

4.  Orbitofrontal Neuroadaptations and Cross-Species Synaptic Biomarkers in Heavy-Drinking Macaques.

Authors:  Sudarat Nimitvilai; Joachim D Uys; John J Woodward; Patrick K Randall; Lauren E Ball; Robert W Williams; Byron C Jones; Lu Lu; Kathleen A Grant; Patrick J Mulholland
Journal:  J Neurosci       Date:  2017-03-07       Impact factor: 6.167

5.  Kv7 channels in the nucleus accumbens are altered by chronic drinking and are targets for reducing alcohol consumption.

Authors:  Natalie S McGuier; William C Griffin; Justin T Gass; Audrey E Padula; Elissa J Chesler; Patrick J Mulholland
Journal:  Addict Biol       Date:  2015-06-23       Impact factor: 4.280

6.  Effects of monoamines on the intrinsic excitability of lateral orbitofrontal cortex neurons in alcohol-dependent and non-dependent female mice.

Authors:  Sudarat Nimitvilai; Marcelo F Lopez; John J Woodward
Journal:  Neuropharmacology       Date:  2018-04-22       Impact factor: 5.250

7.  Prefrontal Cortex KCa2 Channels Regulate mGlu5-Dependent Plasticity and Extinction of Alcohol-Seeking Behavior.

Authors:  Reginald Cannady; Justin T McGonigal; Ryan J Newsom; John J Woodward; Patrick J Mulholland; Justin T Gass
Journal:  J Neurosci       Date:  2017-03-20       Impact factor: 6.167

8.  Chronic Intermittent Ethanol Exposure Enhances the Excitability and Synaptic Plasticity of Lateral Orbitofrontal Cortex Neurons and Induces a Tolerance to the Acute Inhibitory Actions of Ethanol.

Authors:  Sudarat Nimitvilai; Marcelo F Lopez; Patrick J Mulholland; John J Woodward
Journal:  Neuropsychopharmacology       Date:  2015-08-09       Impact factor: 7.853

9.  Chronic Alcohol, Intrinsic Excitability, and Potassium Channels: Neuroadaptations and Drinking Behavior.

Authors:  Reginald Cannady; Jennifer A Rinker; Sudarat Nimitvilai; John J Woodward; Patrick J Mulholland
Journal:  Handb Exp Pharmacol       Date:  2018

10.  Identification and validation of midbrain Kcnq4 regulation of heavy alcohol consumption in rodents.

Authors:  Natalie S McGuier; Jennifer A Rinker; Reginald Cannady; Diana B Fulmer; Sara R Jones; Michaela Hoffman; Patrick J Mulholland
Journal:  Neuropharmacology       Date:  2018-05-25       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.